================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
April 5, 2001
BOSTON SCIENTIFIC CORPORATION
----------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 1-11083 04-2695240
-------- ------- ----------
(State or Other (Commission (IRS Employer
Jurisdiction of File Number) Identification No.)
Incorporation)
One Boston Scientific Place, Natick, Massachusetts 01760
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (508) 650-8000
--------------
================================================================================
ITEM 5. OTHER EVENTS.
On April 5, 2001, Boston Scientific Corporation ("Boston Scientific" or the
"Company") announced that Medinol Ltd. ("Medinol"), manufacturer of the NIR(R)
stent sold exclusively by the Company, had filed a lawsuit against Boston
Scientific and a number of its current and former employees. The allegations
made by Medinol are further described in Medinol's press release dated April 5,
2001, a copy of which is filed as Exhibit 99.1 to this Report. A copy of Boston
Scientific's press release dated April 5, 2001 responding to the lawsuit is
filed as Exhibit 99.2 to this Report.
On April 11, 2001, the Company announced that Jim Tobin, President and CEO
of Boston Scientific, had delivered certain remarks about the Medinol lawsuit to
Boston Scientific's Annual Meeting of Securities Analysts being held at that
time. The remarks made by Mr. Tobin are further described in Boston Scientific's
press release dated April 11, 2001, a copy of which is filed as Exhibit 99.3 to
this Report.
On April 11, 2001, the Company announced the submission of an application
to the U.S. Food and Drug Administration for an Investigational Device Exemption
of its internally developed Express(TM) coronary stent. The submission is
further described in Boston Scientific's press release dated April 11, 2001, a
copy of which is filed as Exhibit 99.4 to this Report.
On April 26, 2001, the Company announced that Medinol added a claim to its
lawsuit alleging that Boston Scientific misappropriated Medinol's NIRFlex(TM)
stent technology and incorporated it into Boston Scientific's internally
developed Express(TM) coronary stent. The allegation made by Medinol and Boston
Scientific's response is further described in Boston Scientific's press release
dated April 26, 2001, a copy of which is filed as Exhibit 99.5 to this Report.
On April 30, 2001, the Company announced that it had filed a lawsuit in the
U.S. District Court for the Southern District of New York charging Medinol, and
its principals, Judith and Jacob Richter, with fraud, multiple breaches of
contract, unfair and deceptive practices, and defamation. The lawsuit is further
described in Boston Scientific's press release dated April 30, 2001, a copy of
which is filed as Exhibit 99.6 to this Report.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(C) EXHIBITS.
Exhibit 99.1 Medinol Ltd. Press Release dated April 5, 2001.
Exhibit 99.2 Boston Scientific Corporation Press Release dated April 5, 2001.
Exhibit 99.3 Boston Scientific Corporation Press Release dated April 11, 2001.
Exhibit 99.4 Boston Scientific Corporation Press Release dated April 11, 2001.
Exhibit 99.5 Boston Scientific Corporation Press Release dated April 26, 2001.
Exhibit 99.6 Boston Scientific Corporation Press Release dated April 30, 2001.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BOSTON SCIENTIFIC CORPORATION
By: /s/ Lawrence J. Knopf
--------------------------------------------
Lawrence J. Knopf
Vice President and Assistant General Counsel
Dated: May 1, 2001
3